ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Session » Systemic Lupus Erythematosus: Clinical Aspects

Meeting: 2012 ACR/ARHP Annual Meeting

Abstract Number: 602
Sexual and Reproductive Health Counseling Among Adolescents with Systemic Lupus Erythematosus
Abstract Number: 603
Cell Bound Complement Activation Products Are Associated with Disease Activity in Systemic Lupus Erythematosus
Abstract Number: 604
Comparing the ACR and the SLICC Criteria for the Classification of SLE  Patients Using Data from an Existing Multi-Ethnic Cohort
Abstract Number: 605
Increased Incidence of Herpes Zoster Among Patients with Systemic Lupus Erythematosus
Abstract Number: 606
Risk Factors Associated with Cervical Human Papillomavirus Infection in Women with Systemic Lupus Erythematosus: The Role of Rituximab
Abstract Number: 607
Activity Index After Renal Failure in a Cohort of 32 Patients with Lupus Nephritis
Abstract Number: 608
Association of Discoid Lupus with Other Clinical Manifestations Among Patients with Systemic Lupus Erythematosus
Abstract Number: 609
Peripheral Neuropathy in Systemic Lupus Erythematosus
Abstract Number: 610
B Lymphocyte Stimulator Levels Are Higher in Caucasian SLE Patients Earlier in Disease Course and Predict Damage Accumulation
Abstract Number: 611
Impaired Diffusion Tensor Imaging Findings in the Corpus Callosum and Cingulum May Underlie Impaired Learning and Memory Abilities in Systemic Lupus Erythematosus
Abstract Number: 612
Thrombosis Recurrence in Systemic Lupus Erythematosus Patients with and without Antiphospholipid Antibodies
Abstract Number: 613
Serum Level of Syndecan-1 Is Associated with Disease Activity in Patients with Systemic Lupus Erythematosus
Abstract Number: 614
Predictors of Systemic Lupus Erythematosus Flares: Baseline Disease Activity and Demographic Characteristics From the Combined Placebo Groups in the Phase 3 Belimumab Trials
Abstract Number: 615
Baseline Laboratory Characteristics From the Combined Placebo Groups in the Phase 3 Belimumab Trials Are Predictive of Severe Flare At 52 Weeks
Abstract Number: 616
Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects
Abstract Number: 617
Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels Reflect Organ Damage in Systemic Lupus Erythematosus
Abstract Number: 618
BAFF/BLyS Gene Expression Predicts Disease Activity in Systemic Lupus Erythematosis Over One Year
Abstract Number: 619
Elevated Plasma Levels of CXCL2 and CXCL10 Have Distinct Predictive Value in Systemic Lupus Erythematosus
Abstract Number: 620
Development of A Quantitative PCR Method to Determine Interferon Signature Metric Status in SLE Patients: Distribution and Clinical & Serological Associations in Two Lupus Clinical Trials
Abstract Number: 621
Prolonged Improvement of Systemic Lupus Erythematosus Following Systematic Administration of Rituximab and Cyclophosphamide
Abstract Number: 622
Headache in Systemic Lupus Erythematosus (SLE): Results From a Prospective, International, Inception Cohort Study
Abstract Number: 623
Endothelial Microparticles As a Biomarker for Endothelial Dysfunction in Active Systemic Lupus Erythematosus
Abstract Number: 624
Excess Health Care Utilization Prior to Diagnosis of Systemic Lupus Erythematosus in England
Abstract Number: 625
Control of Hypertension and Hypercholesterolemia Is Not Associated with a Decreased Rate of Atherosclerotic Vascular Events in Patients with Systemic Lupus Erythematosus
Abstract Number: 626
The Interferon Alpha Gene Signature Is Not Associated with Nor Does It Predict Progression of Coronary Artery Calcium (CAC) or Carotid Intima-Media Thickness (IMT) in Systemic Lupus Erythematosus (SLE)
Abstract Number: 627
Zostavax Vaccine Is Safe in Lupus Patients with Low Disease Activity
Abstract Number: 628
Urinary Heparanase Activity Is Elevated in Patients with Lupus Nephritis and Correlate with Protein Excretion
Abstract Number: 629
Inflammatory Biomarkers of Atherosclerosis and Oxidative Stress Are Associated with Disease Flare in SLE
Abstract Number: 630
Risk Factors Associated with Early Central Nervous System Damage Detected Through Diffusion Tensor Imaging (DTI) in Patients with Systemic Lupus Erythematosus
Abstract Number: 631
Peripheral Neuropathy Due to Systemic Lupus Erythematosus (SLE) Itself: Incidence, Disease Risk Factors and Outcome
Abstract Number: 632
The Effects of Co-Existing Proliferative Histopathology On Membranous Lupus Nephritis
Abstract Number: 633
Missed Work Days in Systemic Lupus Erythematosus
Abstract Number: 634
Adherence to Adult Treatment Panel III Guidelines for Systemic Lupus Patients
Abstract Number: 635
Elevated Transglutaminase Levels On Microparticles From Systemic Lupus Erythematosus Patients
Abstract Number: 636
Retrospective Study of Allogenic Mesenchymal Stem Cells Transplantation in Active and Refractory Lupus Nephritis for Induction Therapy
Abstract Number: 637
Anti-Mullerian Hormone and Ovarian Reserve in Systemic Lupus Erythematosus
Abstract Number: 638
The Progression of Brain MRI Biomarker of Cognitive Impairment (White Matter Hyperintensity) in Systemic Lupus: A Clinical and Imaging Longitudinal Study
Abstract Number: 639
Safety and Efficacy of Epratuzumab in an Open-Label Extension Study (SL0006)
Abstract Number: 640
Association of Body Weight with Cardiovascular Events in Systemic Lupus Erythematosus
Abstract Number: 641
Study of Anti-Müllerian Hormone and Probability of Pregnancy in 112 Systemic Lupus Erythematosus Patients Exposed or Not to Cyclophosphamide
Abstract Number: 642
Effects of Treatment On the Expression of CCL2 and CXCL10 in Systemic Lupus Erythematosus Patients
Abstract Number: 643
Clinical Characteristics for Future Development of Systemic Lupus Erythematosus in Korean Patients with Idiopathic Thrombocytopenic Purpura
Abstract Number: 644
Pulmonary Hypertension in Systemic Lupus Erythematosus: A 6-Year Follow-up Study Cohort
Abstract Number: 645
Altered Soluble Inflammatory Mediators Mark Impending Systemic Lupus Erythematosus Disease Flare in European-American Lupus Patients Who Receive Influenza Vaccination
Abstract Number: 646
Comparison of the Lupusqol and SF-36 Scores As Valid Measures of Change in Health Related Quality of Life
Abstract Number: 647
Adjusted Framingham Risk Factor Scoring for Systemic Lupus Erythematosus: Results from an Inception Cohort Followed for Eight Years
Abstract Number: 648
Atherosclerotic Vascular Events in a Multinational Inception Cohort of Systemic Lupus Erythematosus: Incidence Over a Ten Year Period
Abstract Number: 649
Increased Male-to-Female Ratio in Children Born to Women with Systemic Lupus Erythematosus
Abstract Number: 650
Clinical Variables Associated with Thrombosis At Systemic Lupus Erythematosus Diagnosis. Differences Between Patients with Positive/Negative Lupus Anticoagulant
Abstract Number: 651
Suicidal Ideation in Patients with Systemic Lupus Erythematosus: Incidence and Relationship with Anxiety/Depression Score Disease Activity and Organ Damage
Abstract Number: 652
Serum Rituximab Levels and Efficiency of B-Cell Depletion: Differences Between Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Abstract Number: 653
Longitudinal Analysis of Plasma Factors and Disease Activity Identifies Von Willebrand Factor As A Biomarker of Lupus Flare
Abstract Number: 654
Incidence Studies of Systemic Lupus Erythematosus in Southern Sweden. Have the Tides Turned
Abstract Number: 655
Non-White Race, Younger Age, and Use of Primary and Gynecologic Care Are Associated with Higher Rates of Cervical Cancer Screening in Systemic Lupus Erythematosus Patients At a Public Hospital
Abstract Number: 656
Effects of Nelfinavir On Anti-dsDna Antibody Binding and Pro-Inflammatory Cytokine Gene Expression
Abstract Number: 657
Serial Screening Shows That 28% of Systemic Lupus Erythematosus Adult Patients Carry an Underlying Primary Immunodeficiency
Abstract Number: 1386
Genetic Variation and Coronary Atherosclerosis in Patients with Systemic Lupus Erythematosus
Abstract Number: 1387
Hospitalizations and Reasons for Admission in a Clinical SLE Cohort
Abstract Number: 1388
Diagnostic Accuracy of Anti-dsDNA Antibodies in Unselected Patients with Recent Onset of Rheumatic Symptoms
Abstract Number: 1389
Erythrocyte Sedimentation Rate Is a Predictor of Renal and Overall Systemic Lupus Erythematosus Disease Activity
Abstract Number: 1390
Vitamin D Deficiency Is Not Associated with Nor Does It Predict Progression of Coronary Artery Calcium or Carotid Intima-Media Thickness in Systemic Lupus Erythematosus
Abstract Number: 1391
Anti-Ku Autoantibodies in Systemic Lupus Erythematosus Versus Autoimmune Myositis As Measured by a Novel Chemiluminescence Assay
Abstract Number: 1392
Clinical Correlation with Anti Double Stranded Deoxyribonucleic Acid Via Enzyme Linked Immunoassay Versus Multiplex Immunoassay
Abstract Number: 1393
Predictors of Panniculitis in Systemic Lupus Erythematosus
Abstract Number: 1394
Health Status Burden and Impact of Fatigue On Patient Functioning in SLE Patients From a Phase 1b Study
Abstract Number: 1395
The Validation of a New Simple Disease Activity Tool in Systemic Lupus Erythematosus (SLE): The Lupus Activity Scoring Tool (LAST) As Compared to the Sledai Selena Modification
Abstract Number: 1396
Associates of a History of Thrombosis in Systemic Lupus Erythematosus
Abstract Number: 1397
Risk Factors Associated with Early Central Nervous System Damage Detected Through Perfusion MRI in Patients with Systemic Lupus Erythematosus
Abstract Number: 1398
Inflammatory Back Pain Is Increased in SLE and Associated with Anti-Sm Antibodies
Abstract Number: 1399
Regional Fat Distribution Is Independently Associated with Damage Accrual in Systemic Lupus Erythematosus Female Patients
Abstract Number: 1400
Predictors of Obesity in Systemic Lupus Erythematosus
Abstract Number: 1401
Characterization of Clinical Photosensitivity in Cutaneous Lupus Erythematosus
Abstract Number: 1402
Anti-ApoA1 Antibodies Associate with Disease Activity in Lupus and Are Lower in Patients Taking Hydroxychloroquine: A Longitudinal Analysis of 398 Samples
Abstract Number: 1403
Anti-Nucleosome Antibodies Are Associated with Disease Activity and Hydroxychloroquine Use in Patients with Lupus: A Longitudinal, Multivariate Analysis of 398 Samples
Abstract Number: 1404
There Is an Association Between Disease Activity and Risk of Thromboembolism in SLE
Abstract Number: 1405
Real World Experience Comparing Multiplex Immunobead Assay  versus Immunoflorescence Assay for Anti-Nuclear Antibody Detection At a University Hospital
Abstract Number: 1406
The Cost of Management of Adult Active Systemic Lupus Erythematosus in the UK
Abstract Number: 1407
The Effect of the Antiphospholipid Syndrome (APS) On Survival in Chinese Patients with SLE: A Prospective Study of 679 Patients
Abstract Number: 1408
Monitoring Patients with Systemic Lupus Erythematosus in Clinical Practice: Have You Already Checked the Vaccination Status in Your Patients?
Abstract Number: 1409
A Multicentre Clinical Study of Umbilical Cord Mesenchymal Stem Cells Transplantation in Active Systemic Lupus Erythematosus
Abstract Number: 1410
Relationship Between Individual Organ Damage and Mortality of Systemic Lupus Erythematosus (SLE): A Prospective Cohort Study of 679 Patients
Abstract Number: 1411
Equivalence of Various Language Versions of Lupus Specific Patient Reported Outcomes Measure (LupusPRO)
Abstract Number: 1412
Vascular Cell Adhesion Molecule (VCAM-1) and Angiostatin in Systemic Lupus Erythematosus
Abstract Number: 1413
Clinical Presentation, Treatment and Outcome of Membranous Nephropathy in SLE: A Comparison with Proliferative Lupus Glomerulonephritis in 141 Patients
Abstract Number: 1414
Combination of Mycophenolate Mofetil and Tacrolimus for Refractory Lupus Nephritis: A 12-Month Open-Labeled Trial
Abstract Number: 1415
Effect of Renal Disease On Survival of Patients with Systemic Lupus Erythematosus: A Prospective Cohort Study of 694 Patients
Abstract Number: 1416
Tumor Necrosis Factor Alpha Is Associated with Mood Disorders in Patients with Systemic Lupus Erythematosus
Abstract Number: 1417
Favorable Response to Belimumab At Three Months
Abstract Number: 1418
Directed Intuitive Assessment of Lupus (the DIAL system for real world clinics) Correlates Well with BILAG and SLEDAI
Abstract Number: 1419
Infections Increase Risk of Arterial and Venous Thromboses in Systemic Lupus Erythematosus Patients: 4925 Patient Years of Follow-up
Abstract Number: 1420
Ethnicity and B Cell Depletion Therapy in Systemic Lupus Erythematosus
Abstract Number: 1421
Antimalarials Protect Systemic Lupus Erythematosus Patients From Damage Accrual During the First Five Years of the Disease
Abstract Number: 1422
Clinical Associations of Anti-Smith Antibodies in Profile: A Multiethnic Lupus Cohort
Abstract Number: 1423
Vascular Thrombosis and Pregnancy Morbidity in Patients with Systemic Lupus Erythematosus with Positive Antiphospholipid Profile and Thrombocytopenia
Abstract Number: 1424
Prevalence and Clinical Significance of Severe Infection in Patients with Systemic Lupus Erythematosus: Preliminary Data From Relesser (Registry of lupus of the Spanish Society of Rheumatology)
Abstract Number: 1425
Circulating Free Protein S Levels May Be Linked to Cardiovascular Events and Venous Thrombosis in SLE
Abstract Number: 1426
The Clinical Relevance of a “False Negative” Enzyme Linked Immunoassay: Which Antinuclear Antibody Screening Test Is Preferred by Rheumatologists in an Integrated Health System?
Abstract Number: 1427
Late Onset Systemic Lupus Erythematosus: Is It Actually A Milder Variant?
Abstract Number: 1428
Long-Term Outcomes of Children Born to Women with Systemic Lupus Erythematosus
Abstract Number: 1429
Women with Systemic Lupus Erythematosus (SLE) May Have Different Predictors of Risk for Progression of Aorta Calcium (AS) Than Women without SLE
Abstract Number: 1430
Women with Systemic Lupus Erythematosus (SLE) May Have Different Predictors of Risk for Progression of Coronary Artery Calcium (CAC)Than Women without SLE
Abstract Number: 1431
Single Photon Emission Computed Tomography Contributes to Clinical Assessments in Neuropsychiatric Systemic Lupus Erythematosus Patients
Abstract Number: 1432
Safety and Efficacy of Etanercept in Systemic LUPUS Erythematosus
Abstract Number: 1433
Persistent Dyslipidemia Is a Risk Factor of Progression to Chronic Kidney Disease in Patients with Lupus Nephritis
Abstract Number: 1434
Cardiovascular Morbidity in a Long-Term Follow-up Cohort of Systemic Lupus Erythematosus Patients in Southern Sweden
Abstract Number: 1435
Identifying Systemic Lupus Erythematosus Patients At Higher Risk of Coronary Artery Disease
Abstract Number: 1436
Application of European League Against Rheumatism Recommendations for the Management of Systemic Lupus Erythematosus Patients with Neuropsychiatric Involvement May Limit Unnecessary Diagnostic Testing and Curve Intensification of Immunosuppressive Therapy of Unclear Benefit
Abstract Number: 1437
Majority of Lupusqol Domains Are Negatively Correlated with Systemic Lupus Activity Questionnaire (SLAQ) Score
Abstract Number: 2236
Cross Cultural Validation of English and French Versions of a Disease Specific Patient Reported Outcome Measure for Lupus in Canada
Abstract Number: 2237
Application and Feasibility of Proposed Systemic Lupus Erythematosus Reproductive Health Care Quality Indicators At a Public Urban Rheumatology Clinic
Abstract Number: 2238
Alpha-Chlorofatty Acid Does Not Correlate with Baseline Subclinical Cardiovascular Disease in Systemic Lupus Erythematosus
Abstract Number: 2239
Characterization of Pure Membranous Lupus Nephritis: A Cohort of 150 Patients
Abstract Number: 2240
Systematic Review of Skin Nontuberculous Mycobacteria Infection in Systemic Lupus Erythematosus: An Unusual Skin Infection Mimicking Lupus Vasculitis
Abstract Number: 2241
Efficacy of Belimumab in Systemic Lupus Erythematosus Patients with High Baseline Disease Activity
Abstract Number: 2242
Clinical Manifestations and Predictive Factors for Response to Induction Therapy and Maintenance of Remission in ISN/RPS Class V Lupus Nephritis
Abstract Number: 2243
A Comparison of Systemic Lupus Erythematosus (SLE) Patients Achieving Prolonged Clinical Quiescence (PCQ) On and off Corticosteroids and/or Immunosuppressive Medications
Abstract Number: 2244
Predicting Sjögren’s Syndrome At Diagnosis of Systemic Lupus Erythematosus
Abstract Number: 2245
Vitamin D Deficiency Is Associated with, but Does Not Predict, Change in hsCRP in Systemic Lupus Erythematosus (SLE)
Abstract Number: 2246
Real World Experience with Belimumab in the Management of Systemic Lupus Erythematosus (SLE): A Single Center, Observational, Post-Marketing Study
Abstract Number: 2247
The First Report of Desensitization to Trimethoprim/Sulfamethoxazole in Patients with Systemic Lupus Eryhtematosus
Abstract Number: 2248
Serum Phosphatidylserine-Specific Phospholipase A1 (PS-PLA1) Identified As a Novel Biomarker for Systemic Lupus Erythematosus (SLE)
Abstract Number: 2249
Comparison of Mycophenolate Mofetil and Intravenous Cyclophosphamide As Induction Therapy in Korean Patients with Lupus Nephritis
Abstract Number: 2250
A Clinical Analysis of Adult Patients with Autoimmune- and Infection-Associated Hemophagocytic Lymphohistiocytosis
Abstract Number: 2251
High Sensitivity C-Reactive Protein, Disease Activity and Cardiovascular Risk Factors in Systemic Lupus Erythematosus
Abstract Number: 2252
Epratuzumab-Treated Systemic Lupus Erythematosus Patients Report Improvements in Health-Related Quality of Life: Final Results from an Open-Label Extension Study (SL0006)
Abstract Number: 2253
Metabolic Syndrome Is Not Only a Risk Factor for Cardiovascular Events in Systemic Lupus Erythematosus but Also Associated with Cumulative Organ Damage: A Cross-Sectional Analysis of 311 Patients
Abstract Number: 2254
Discoid Lupus in Patients with Systemic Lupus Erythematosus
Abstract Number: 2255
Apolipoprotein B Containing Lipoprotein Subclasses and Subclinical Atherosclerosis in Patients with Systemic Lupus Erythematosus (SLE)
Abstract Number: 2256
A Population of IL-21 Producing CD4+ T Cells Correlates with Disease Damage in Systemic Lupus Erythematosus (SLE) Patients
Abstract Number: 2257
Association of Low Vitamin D with High Disease Activity in an Australian Systemic Lupus Erythematosus Cohort
Abstract Number: 2258
Risk Factors for Total Joint Replacement in Systemic Lupus Erythematosus Patients with Avascular Necrosis
Abstract Number: 2259
Limitations of Current Treatment for Systemic Lupus Erythematosus: A Patient and Physician Survey
Abstract Number: 2260
Serum DNAse I Anti DNAse I Antibodies , CRP and Antibodies to CRP Relation to Disease Activity in Systemic Lupus Eryhtematous: Longitudinal Studies
Abstract Number: 2261
Ovarian Reserve Markers in Reproductive Age Women with Systemic Lupus Erythematosus
Abstract Number: 2262
Hypogammaglobulinemia in Pediatric Systemic Lupus Erythematosus
Abstract Number: 2263
The Association Between Prior Pregnancy Morbidity and Cardiovascular Events in Women with Systemic Lupus Erythematosus
Abstract Number: 2265
Clinical Manifestations of Systemic Lupus Erythematosus Vary Based On Age of Disease Onset
Abstract Number: 2266
Outcome of Renal Transplantation in Lupus Patients with Positive and Negative Serology: Survival of the Graft and Patients After Transplant

« View all sessions from this meeting

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences